COLL

Collegium Pharmaceutical Stock Price

24.92
-0.23 (-0.91%)
Upgrade to Real-Time
Regular Market
24.92

Low
15.66

52 Week Range

High
26.91

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Collegium Pharmaceutical Inc COLL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.23 -0.91% 24.92 12:15:50
Open Price Low Price High Price Close Price Prev Close
25.22 24.65 25.22 25.15
Bid Price Ask Price Spread News
24.85 24.91 0.06 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
746 97,789 $ 25.07 $ 2,451,906 - 15.66 - 26.91
Last Trade Time Type Quantity Stock Price Currency
12:15:56 1 $ 24.85 USD

Period:

Draw Mode:

Collegium Pharmaceutical Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 878.37M 35.25M 23.91M $ 310.02M $ 44.92M 0.76 21.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 71.06k 3.30%

more financials information »

Collegium Pharmaceutical News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical COLL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week23.5325.6323.5324.83286,4291.395.91%
1 Month25.2925.6322.2024.02198,110-0.37-1.46%
3 Months22.4325.6621.2723.35245,5692.4911.1%
6 Months24.5026.9121.15524.18404,2360.421.71%
1 Year16.8426.9115.6622.13359,6218.0847.98%
3 Years20.1126.9110.0118.73410,2784.8123.92%
5 Years11.8629.907.3717.91430,80613.06110.12%

Collegium Pharmaceutical Description

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.


Your Recent History
NASDAQ
COLL
Collegium ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.